Suivre
Richard B. Schwab
Richard B. Schwab
Senior Medical Director, Genentech
Adresse e-mail validée de gene.com
Titre
Citée par
Citée par
Année
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
5782016
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively …
R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ...
JAMA oncology 6 (5), 676-684, 2020
5182020
Reproductive risk factors and breast cancer subtypes: a review of the literature
KN Anderson, RB Schwab, ME Martinez
Breast cancer research and treatment 144, 1-10, 2014
4772014
Adaptive randomization of neratinib in early breast cancer
JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ...
New England Journal of Medicine 375 (1), 11-22, 2016
3582016
HER2 aberrations in cancer: implications for therapy
M Yan, BA Parker, R Schwab, R Kurzrock
Cancer treatment reviews 40 (6), 770-780, 2014
2542014
A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1: the caveolin scaffolding domain is both necessary and sufficient for membrane …
A Schlegel, RB Schwab, PE Scherer, MP Lisanti
Journal of Biological Chemistry 274 (32), 22660-22667, 1999
1961999
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
S Kato, KH Kim, HJ Lim, A Boichard, M Nikanjam, E Weihe, DJ Kuo, ...
Nature communications 11 (1), 4965, 2020
1942020
Exploring the landscape of focal amplifications in cancer using AmpliconArchitect
V Deshpande, J Luebeck, NPD Nguyen, M Bakhtiari, KM Turner, ...
Nature communications 10 (1), 392, 2019
1912019
Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
S Zhang, B Cui, H Lai, G Liu, EM Ghia, GF Widhopf, Z Zhang, CCN Wu, ...
Proceedings of the National Academy of Sciences 111 (48), 17266-17271, 2014
1902014
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ...
The Lancet Oncology 23 (1), 149-160, 2022
1872022
Molecular tumor board: the University of California San Diego Moores cancer center experience
M Schwaederle, BA Parker, RB Schwab, PT Fanta, SG Boles, GA Daniels, ...
The oncologist 19 (6), 631-636, 2014
1862014
Gene-target recognition among members of the myc superfamily and implications for oncogenesis
RC O'Hagan, N Schreiber-Agus, K Chen, G David, JA Engelman, ...
Nature genetics 24 (2), 113-119, 2000
1752000
Precision oncology: The UC San Diego moores cancer center predict experience
M Schwaederle, BA Parker, RB Schwab, GA Daniels, DE Piccioni, ...
Molecular cancer therapeutics 15 (4), 743-752, 2016
1682016
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
M Schwaederle, H Husain, PT Fanta, DE Piccioni, S Kesari, RB Schwab, ...
Oncotarget 7 (9), 9707, 2016
1602016
Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia
RP Wu, T Hayashi, HB Cottam, G Jin, S Yao, CCN Wu, MD Rosenbach, ...
Proceedings of the National Academy of Sciences 107 (16), 7479-7484, 2010
1552010
Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia
RP Wu, T Hayashi, HB Cottam, G Jin, S Yao, CCN Wu, MD Rosenbach, ...
Proceedings of the National Academy of Sciences 107 (16), 7479-7484, 2010
1552010
Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer
V Padler-Karavani, N Hurtado-Ziola, M Pu, H Yu, S Huang, S Muthana, ...
Cancer research 71 (9), 3352-3363, 2011
1502011
Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis
BT Mausbach, RB Schwab, SA Irwin
Breast cancer research and treatment 152, 239-246, 2015
1462015
Use of liquid biopsies in clinical oncology: pilot experience in 168 patients
M Schwaederle, H Husain, PT Fanta, DE Piccioni, S Kesari, RB Schwab, ...
Clinical cancer research 22 (22), 5497-5505, 2016
1432016
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
L Pusztai, C Yau, DM Wolf, HS Han, L Du, AM Wallace, E String-Reasor, ...
Cancer cell 39 (7), 989-998. e5, 2021
1422021
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20